Efficacy of paired tumor and germline testing in evaluation of patients with Lynch-like syndrome in a large integrated healthcare setting

被引:0
作者
Holly Carwana
Elizabeth Hoodfar
JoAnn Bergoffen
Dan Li
机构
[1] Kaiser Permanente Northern California,Department of Genetics
[2] Kaiser Permanente Northern California,Department of Genetics
[3] Kaiser Permanente Northern California,Department of Gastroenterology
[4] Kaiser Permanente Northern California,Division of Research
来源
Familial Cancer | 2021年 / 20卷
关键词
Lynch-like syndrome; Lynch syndrome; Colorectal cancer; Pathogenic variant; Somatic testing; Paired testing;
D O I
暂无
中图分类号
学科分类号
摘要
Patients with mismatch repair (MMR) deficient colorectal cancer (CRC) without detectable germline pathogenic variants (PVs) or likely pathogenic variants (LPVs) in MMR genes are often labeled as Lynch-like syndrome (LLS). We sought to evaluate the efficacy of paired tumor and germline testing in risk stratification of patients with LLS in a large, community-based, integrated healthcare setting. Through the universal screening program for Lynch syndrome at Kaiser Permanente Northern California, we identified all patients with MMR deficient colorectal tumors without detectable germline PVs or LPVs between April 2011 and October 2018. These patients were categorized as LLS and were offered paired tumor and germline testing. Risk stratification and patient management were assessed upon completion of all testing. Of the 50 patients with LLS who underwent paired tumor and germline testing, 62% (n = 31) were categorized as sporadic, 6% (n = 3) had Lynch syndrome, and 32% (n = 16) remained inconclusive. Among the sporadic cases, 65% (n = 20) had a PV (n = 18) or LPV (n = 2) in combination with loss of heterozygosity while 35% (n = 11) had two somatic PVs/LPVs involving the same MMR gene. Our findings showed paired tumor and germline testing resolved the etiology in the majority of patients and is a valuable strategy in risk stratification and management of patients with LLS. Further studies are needed to assess the optimal application of paired testing in different practice settings, particularly with evolving technology and decreasing cost of molecular sequencing.
引用
收藏
页码:223 / 230
页数:7
相关论文
共 67 条
[1]  
Ladabaum U(2015)American gastroenterological association technical review on the diagnosis and management of Lynch syndrome Gastroenterology 149 783-813
[2]  
Ford JM(2000)Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer Gastroenterology 118 829-834
[3]  
Martel M(2001)Cancer risk in mismatch repair gene mutation carriers Fam Cancer 1 57-60
[4]  
Jarvinen HJ(2008)The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome Int J Cancer 123 444-449
[5]  
Aarnio M(2006)Prophylactic surgery to reduce the risk of gynecological cancers in the Lynch syndrome N Engl J Med 354 261-269
[6]  
Mustonen H(2019)Comparison of universal versus age-restricted screening of colorectal tumors for Lynch syndrome using mismatch repair immunohistochemistry: a cohort study Ann Intern Med 171 19-26
[7]  
Watson P(2008)Feasibility of screening for Lynch syndrome among patients with colorectal cancer J Clin Oncol 26 5783-5788
[8]  
Lynch H(2005)Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer) N Engl J Med 352 1851-1860
[9]  
Watson P(2020)What is Lynch-like syndrome and how should we manage it? Clin Gastroenterol Hepatol 18 294-296
[10]  
Vasen HF(2013)The mystery of mismatch repair deficiency: Lynch or Lynch-like? Gastroenterology 144 868-870